Role of ALK Inhibitors in Anaplastic Large Cell Lymphoma—Experience from an Indian Center
نویسندگان
چکیده
Anaplastic large cell lymphoma (ALCL) is the second most common type of peripheral T and an aggressive mature lymphoma. About 50 to 70% systemic ALCLs are anaplastic kinase positive (ALK +), proportion even higher in pediatric population. The 5-year survival after chemotherapy around 70 80%. But there a subgroup ALK+ ALCL patients who refractory chemotherapy. Brentuximab vedotin approved agent for such patients. activity ALK inhibitors non-small lung cancer well known has been use. efficacy safety + largely under-reported. Here we have reported our experience use relapsed ALCL.
منابع مشابه
Pathobiology of ALK+ anaplastic large-cell lymphoma.
Anaplastic large-cell lymphoma (ALCL) was initially recognized on the basis of morphologic features and the consistent expression of CD30. It then became evident that the majority of these tumors are derived from lymphoid cells of T or null immunophenotype. The subsequent finding that t(2;5)(p23;q35) occurs in 40% to 60% of ALCL patients established a distinct clinicopathologic entity. This chr...
متن کاملALK-positive anaplastic large cell lymphoma: an evolving story.
The current classification of lymphoid neoplasms is based on the integrated utilisation of morphological, immunohistochemical, genetic and clinical criteria to define disease entities. Anaplastic large cell lymphoma is a paradigm for the identification of a disease entity based on morphological observations and immunophenotype, which paved the way for the subsequent discovery of the characteris...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: South Asian Journal of Cancer
سال: 2023
ISSN: ['2278-330X', '2278-4306']
DOI: https://doi.org/10.1055/s-0042-1758353